New England Journal of Medicine· 2014Q1
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- 1,262citations
- Q1SCImago
- 2014year
Short summary
Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) is often caused by mutations in BTK at the drug's binding site (C481S) or in the downstream PLCγ2 gene (R665W, L845F).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Genetics
GeneticsMedicine